Delivery Order SPE2DB25D3109-SPE2DB26FP4PV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for RINVOQ ER 15 mg tablets (30-unit bottles) under a firm fixed-price contract valued at $10,362.56. This is a non-set-aside competitive award with an ultimate completion date of July 30, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose) valued at $3,111.66 under a firm fixed-price contract. The award, announced on August 6, 2025, with an ultimate completion date of August 7, 2025, represents a non-competitive, non-set-aside delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for RINVOQ ER 15 mg tablets (quantity 30) with a ceiling value of $96,729.24. This firm fixed price delivery order, set to be completed by November 4, 2025, is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 through December 2026. The award is non-competitive and represents a continuation...
- The Defense Logistics Agency awarded a delivery order valued at $5,520.99 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 6, 2025, with completion scheduled for August 7, 2025. This competitive award uses firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. The delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $9,728.70 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,844.37 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This is a firm fixed price, non-set-aside contract performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $42,368.91 to AmerisourceBergen Drug Corp for RINVOQ ER 30 MG tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed price, non-set-aside delivery order executed by the prime contractor, whose corporate office is located in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a $32,046.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 22, 2025, with completion targeted for July 23, 2025. This non-competitive, non-set-aside delivery order represents a child contract action under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement valued through December 2026. The product will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count unit dose packaging) with a contract value of $36,032.60. This is a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle that extends through...
- SPE2DB25D3109Indefinite Delivery Contract
- SPE2DB25D3109-SPE2DB26FP4PVDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for RINVOQ ER 15 mg tablets (30-count units) valued at $6,223.32 under a firm fixed-price contract with an ultimate completion date of November 5, 2025. This is a non-set-aside, competitively awarded delivery order issued as a child contract against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The prime vendor agreement serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company maintains an extensive portfolio of federal contract awards with the Defense Logistics Agency Medical Supply Chain, delivering brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. RINVOQ (upadacitinib) is a JAK inhibitor used primarily for treating rheumatoid arthritis and inflammatory bowel disease, representing the type of specialty pharmaceutical products that AmerisourceBergen routinely supplies to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 11/4/25 |